Biogen's Zinbryta Gets EU Nod – But Where Will It Fit In?
Biogen and AbbVie Inc.'s multiple sclerosis therapy, Zinbryta (daclizumab), has been given a green light for use in Europe – but what gap can this new drug fill in a crowded therapy space?
You may also be interested in...
Antibody was approved in the US with a liver safety warning while EU regulators recently limited the drug's use. Now, EMA has begun an urgent review of reports of inflammatory brain disorders related to Zinbryta.
New multiple sclerosis drug Zinbryta adds a European approval to its regulatory status, but is targeting a market where there are already various options for treating relapsing-remitting MS patients.
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.